Niemann-Pick type C disease (NPC) is a fatal autosomal recessive disorder characterized by a defect in the intracellular transport of lipoproteins leading to the accumulation of lipids in diverse tissues. A visceral and neuronal phenotype mimicking human NPC1 disease has been described in NPC1 mutant mice. These mice are by now the most widely used NPC1 rodent model to study NPC and developmental compounds against this devastating disease. Here we characterized NPC1 À/À mice for their hepatic and neuronal phenotype to confirm the stability of the phenotype, provide a characterization of disease progression and pinpoint the age of robust phenotype onset. Animals of 4e10 weeks of age were analyzed for general health, motor deficits as well as hepatic and neuronal alterations with a special focus on cerebellar pathology.
Background
The classical Niemann-Pick type C disease (NPC) is a fatal autosomal recessive disorder that affects approximately 1 in 90,000 live births in western countries while the late-onset form of the disease has an incidence rate of up to 1 in 20,000 . Mutations in the NPC1 gene account for approximately 95% while mutations in the NPC2 gene are responsible for the remaining 5% of NPC cases (for review see (Wraith et al., 2009) ). NPC1 mutations cause a loss of protein function (Carstea et al., 1997) resulting in a disturbed transport of several lipids like cholesterol, sphingomyelin, glucosylceramide and sphingosine making the NPC1 protein a multi-substrate transporter (Lloyd-Evans and Platt, 2010) . NPC1 localizes to the late endosome and the periphery of lysosomes (Zhang et al., 2003) causing increased cholesterol levels in visceral organs but decreased levels in the brains white matter (Vanier, 1983 (Vanier, , 1999 . Thus, spleen and liver, as well as the brain are almost universally affected, leading to a variable heterogeneous symptomatology and progression (Mengel et al., 2013) . The clinical presentation is extremely heterogeneous, with an age of onset ranging from the perinatal period until adult age (Vanier, 2010) . Similarly, the lifespan of patients varies between a few days to over 60 years, although a majority of cases die between 10 and 25 years of age (Group et al., 2009) .
A visceral and neuronal phenotype mimicking human NPC1 disease has been described in NPC1 mutant mice on a Balb/C background (BALB/cNctrNpc1<m1N>/J), presenting the first mouse model of NPC1 that has been used for most NPC1 studies since then (Loftus et al., 1997; Zervas et al., 2001) . Animals have an almost total absence of the NPC1 protein and display pathological hallmarks of the disease (Loftus et al., 1997) . Due to the shortened lifespan of only 10e14 weeks, NPC1
À/À mice have a more severe disease progression than the vast majority of patients (Smith et al., 2009) .
During the first month of life NPC1 À/À mice present only minor phenotypical differences compared to wildtype animals (WTs) like reduced body weight and first signs of neuronal loss (Ong et al., 2001; Nicoli et al., 2016) . At 5e6 weeks of age tremor, ataxic gait and motor deficits start. By 7e8 weeks, NPC1 À/À mice start losing weight and motor control problems become obvious (Loftus et al., 1997; Voikar et al., 2002; Paul et al., 2004; Li et al., 2005; Smith et al., 2009) . NPC1 À/À mice present accumulation of unesterified cholesterol in different tissues, abnormalities in lysosomal enzyme levels, increased activity of hepatic enzymes and decreased levels of triacylglycerides (Pentchev et al., 1980; Amigo et al., 2002; Beltroy et al., 2005 Beltroy et al., , 2007 Kulinski and Vance, 2007) . At present there is no cure for Niemann-Pick disease, and the only available treatment, Miglustat, can alleviate symptoms but does not cure the disease ( (Wraith et al., 2010; Bowman et al., 2015; Sedel et al., 2016; Bowman et al., 2018) , for review see (Lyseng-Williamson, 2014) ).
In this study, we performed an in-depth biochemical and behavioral characterization over age of NPC1 À/À mice to confirm the stability of the phenotype, provide a characterization of disease progression and pinpoint the age of robust phenotype presence in this mouse model which will support future therapeutic strategies.
Results

General health and motor deficits of NPC1 L/L mice over age
To evaluate the health status of NPC1 À/À mice and wildtype (WT) littermates, animals' body weight and body temperature were measured weekly for 6 weeks. Both NPC1 À/À and WT mice showed a similar body weight gain during the first 4 weeks of measurement: the weight gain at 6 weeks of age was maintained more or less constant until mice were 8 weeks old. From 8 weeks onwards, NPC1 À/À mice were significantly lighter compared to WT littermates (Fig. 1A) . The body temperature stayed constant in both groups until the animals were 9 weeks old. From that time onwards, NPC1 À/À mice showed a significantly lower body temperature compared to WT littermates (Fig. 1B) .
To evaluate the general activity of NPC1 À/À mice, the nesting behavior was measured over age. In WT littermates, an increase in the nesting score during the first two weeks could be observed. Afterwards, the score stayed constant until the age of 10 weeks. On the other hand, NPC1 À/À mice showed a similar nesting score at 5 and 6 weeks of age compared to WT littermates. Nonetheless, a significantly disturbed nesting behavior was observed from the eighth week onward, reaching the worst score at the age of 9 weeks (Fig. 1C ).
To assess motor coordination, the Rota Rod and Beam Walk test were performed.
NPC1
-/ mice showed a progressive decrease in the latency to fall off of the rod.
When compared to WT littermates, significant differences were observed at 8e10
weeks of age (Fig. 1D ).
The Beam Walk test was performed only with 7 week old animals since older animals are hardly able to stay on the beam. At this age, a significant difference in motor Fig. 2A) . Furthermore, total cholesterol levels were significantly higher in the liver of NPC1 À/À mice compared to WT littermates (Fig. 2B) . In order to study possible brain alterations in NPC1 À/À mice, the brain was weighed and the levels of total cholesterol and Ab were measured in 6 week old mice compared to age-matched WT littermates. The weight of the cerebellum and cortex was significantly lower in NPC1 À/À mice compared to WT littermates (Fig. 3A) . The level of total cholesterol was assessed in different brain regions of NPC1 À/À mice resulting in a significant decrease only in the hippocampus compared to WT littermates ( Fig. 3B) . Furthermore, Ab levels were significantly increased in the hippocampus of NPC1 À/À mice but not in the cerebellum or cortex (Fig. 3C ).
Progressive neuroinflammation in NPC1 L/L mice
Cytokine profiles were assessed in the cerebellum and hippocampus of 6 week old NPC1 À/À and WT animals. IL-12p70 was significantly decreased in the cerebellum but increased in the hippocampus of NPC1 À/À mice compared to WT littermates.
Nevertheless, when data were analyzed by t-test, also IL-10 was significantly reduced while IL-1b and KC were significantly increased in the cerebellum of NPC1 À/À mice compared to WT littermates (Fig. 4A , t-test significances not labeled). In the hippocampus, IFN-g, KC and TNF-a were significantly increased in NPC1 À/À mice compared to WT littermates when analyzed by t-test (Fig. 4B , t-test significances not labeled).
Quantitative immunofluorescence was used to evaluate neuroinflammation during disease progression. 4, 7 and 10 week old NPC1 À/À and 10 week old WT animals were analyzed for GFAP and CD45 expression to visualize astrocytosis and activated microglia, respectively. In the cerebellum, 10 week old NPC1 À/À mice showed higher, but not significant total GFAP signal than WT littermates of the same age. In NPC1 À/À mice, the GFAP levels remained stable over time (Fig. 4C ). Hippocampal GFAP levels did also not significantly change over age (Fig. 4D ). CD45 labeling showed a significant increase of total signal over age in the hippocampus but not in the cerebellum of NPC1 À/À animals (p ¼ 0.0568; Fig. 4E ,F).
Quantitative analysis of MAP2 total signal showed a slight decrease over age in NPC1 À/À mice compared to WT littermates but data were not statistically significant (data not shown). 
Progressive cerebellar alterations of NPC1 L/L mice
To evaluate the disease progression in adolescent NPC1 À/À mice, 6 and 10 week old NPC1 À/À and WT animals were analyzed. NPC1 À/À mice showed a robust decreased cerebellar weight compared to WT mice at 10 weeks of age ( Representative images of the cerebellum show APP, Calbindin D-28k and DAPI labeling to visualize APP, Purkinje cell loss and nuclei for counterstaining (Fig. 5E ).
In summary, our results demonstrate that NPC1 À/À mice show diminished body weight and temperature in week 9 and 10, respectively. Furthermore, animals present robust motor deficits at 8 weeks of age. Already at the age of 6e7 weeks NPC1 À/À mice also show an increased liver size and higher cholesterol and hepatic enzyme levels. The brain of NPC1 À/À mice on the other hand presents a decreased weight compared to WT littermates and total cholesterol levels are diminished in the the cerebellum (C) and hippocampus (D) of 4, 7 and 10 week old NPC1 À/À mice and 10 week old WT littermates. Quantification of CD45 labelled microglia and leukocytes in the cerebellum (E) and hippocampus (F) of 4, 7 and 10 week old NPC1 À/À mice and 10 week old control animals. A,B: n ¼ 6, Twoway ANOVA followed by Bonferroni's posthoc test. Mean þ SEM. CeF: n ¼ 3, One-way ANOVA followed by Bonferroni's posthoc test. Mean AE SEM. *compared to WT; # changes over age; AeF: *p < 0.05; **p < 0.01. G: Representative images showing co-labeling of the cerebellum with GFAP þ MAP2 þ CD45, labelled astrocytes þ principal neurons þ microglia/leukocytes, respectively of 7 week old NPC1 À/À and WT littermates. Scale bar: 1,000 mm.
hippocampus. On the contrary, Ab1-40, IL-12p70 and activated microglia levels are increased in that same brain region. The cerebellum is simultaneously characterized by highly increased astrocytosis, increased Ab1-40 and decreasing Calbindin D-28k levels. 
Discussion
In this study, we performed a behavioral and biochemical characterization of NPC1 À/À mice to provide an overview of the hepatic and neuronal phenotype of NPC1 À/À mice on a Balb/C background over age. The aim was to gain a better understanding of disease pathology and progression in this model in order to improve future therapeutic strategies.
Firstly, we focused on the general health and behavioral changes. Body weights were decreased at the age of 9 weeks compared to WT littermates. These results and the observed body weight curve over age is comparable with already published results and thus indicates a very robust and stable phenotype of NPC1 À/À mice (Nicoli et al., 2016) . Nest construction is widespread throughout the animal kingdom. For small rodents, nests are important for reproduction and shelter as well as for heat conservation, since rodents are very vulnerable to heat loss due to their small size. Nesting behavior has been shown to be sensitive to brain lesions, pharmacological agents and genetic mutations (Deacon, 2006) . NPC1 À/À mice showed a significantly decreased nesting behavior when compared to WT littermates at 8 weeks of age. These results
show that NPC1 À/À mice do have an impaired general health. Differences in nest building can be observed even before the onset of body weight loss and body temperature decrease and is thus a first indicator of disturbed wellbeing. Retaining the nest building activity requires sufficient motor skills for shredding the nest material.
A decreased nest building activity can therefore depend on uncoordinated higher motor functions, or the motivation to organize the bedding into a nest structure for protection and warmth (Deacon, 2006; Lopez et al., 2011) . Motor skills of NPC1 À/À mice were hence analyzed next since NPC patients often present progressive functional limitations that may include difficulties with gait, balance and coordination (Sansare et al., 2018) . In the Rota Rod test, NPC1 À/À mice showed a progressive decrease in the latency to fall off the rod, which indicates a progressive increase of motor deficits. A robust phenotype in the Rota Rod test could be observed at the age of 8 weeks validating our previous analyses (Rabl et al., 2016) . Analysis of NPC1 À/À mice by other groups showed first motor deficits in the Rota Rod test already at the age of 7 weeks (Elrick et al., 2010; Hung et al., 2016 Since the most common clinical visceral symptom of NPC is hepatosplenomegaly in combination with an altered metabolism of cholesterol and glycolipids in the liver (Elleder et al., 1984; Garver et al., 2007) , these parameters were analyzed in NPC1 À/À mice. In the here presented data, the liver of NPC1 À/À mice weighed significantly more and presented significantly increased cholesterol levels compared to WT littermates by the age of 6 weeks. Earlier analyses by others revealed an increase in liver weight as early as 4 weeks of age that starts to decrease with decreasing body weight at 8 weeks of age while cholesterol levels progressively increase over age (Miyawaki et al., 1983; Xie et al., 1999) . Because NPC1 À/À mice do not present the NPC1/2 transfer complex, the cells are unable to export the cholesterol from the late endosomes (Kwon et al., 2009) , resulting in this observed phenotype. Plasma aspartate (AST), alanine aminotransferase (ALT) and alkaline phosphatase (AP) tests have become standards and are routinely used for diagnosis of liver diseases since all three enzymes are increased in most forms of liver injury (Williams and Hoofnagle, 1988) . Consequently, the levels of the hepatic enzymes, AST, ALT and AP in the plasma of NPC1 À/À mice are strongly increased at an age of 6 weeks validating results by Garver and colleagues (Garver et al., 2007) , who state that the presence of liver damage is characterized by a significant increase in the concentration of ALT and AST in the plasma of NPC1 À/À mice already at 5 weeks of age. These results could be confirmed by others (Beltroy et al., 2005 (Beltroy et al., , 2007 . Since we observed a very strong increase in liver enzyme levels at the age of 6 weeks, the time differences between our results and Garver and colleagues, suggest a progressive increase of this pathological feature in NPC1 À/À mice (Garver et al., 2007) . Thus, we show that liver damage in NPC1 À/À mice is a strong phenotype that can be evaluated by different markers. The observed hepatic pathology of NPC1 À/À mice seems to be comparable with the pathology observed in NPC patients (vom Dahl and Mengel, 2010) , suggesting a strong translational value of these alterations.
Since the disease is not only characterized by a visceral but also neuronal phenotype, the brain of NPC1 À/À mice was analyzed next. Contrary to observations in the liver, the brain of 6 week old NPC1 À/À mice weighed less compared to WT littermates. This is in accordance with results by Luan and coworkers, who already showed a diminished brain weight in 8 week old NPC1 À/À mice (Luan et al., 2008 ). Xie and colleagues could even find first hints of a reduced brain weight in NPC1 À/À mice at the age of 3 weeks (Xie et al., 1999) . Reduced cerebellar weight was already shown to be related to a defective cerebellar granule cell proliferation (Nusca et al., 2014 ) but might also be related to the observed Purkinje cell loss in NPC1 À/À mice.
Purkinje cells are some of the largest neurons in the human brain exhibiting a dense dendritic synaptic network connecting with other cerebellar neurons (Tyrrell and Willshaw, 1992 ). Thus, it should be analyzed in more detail if the loss of Purkinje cells observed in NPC1 À/À mice may lead to the loss of several of the connecting neurons, which would in turn lead to a strong decrease of the Purkinje cell layer and brain weight. Purkinje cell degeneration is indeed the most apparent cerebellar pathology in NPC1 animal models (Higashi et al., 1993; Sarna et al., 2003) .
Moreover, cell specific deletion of the Npc1 gene in mature cerebellar Purkinje cells was shown to lead to an age-dependent Purkinje cell loss and impairments in motor skills (Elrick et al., 2010) . Consequently, we assessed the levels of Calbindin D-28k, a marker of Purkinje cells and found a progressive decrease over age. This decline is significant at 7 weeks of age, the same age at which motor deficits are first observed. This is in agreement with published results by others that already showed a severe loss of Purkinje cells in NPC1 À/À mice (Sarna et al., 2003; Kodam et al., 2010) .
Some studies have shown that NPC disease exhibits some intriguing parallels with
Alzheimer's disease (AD), the most common form of dementia. Among these characteristics are Ab metabolism dysfunctions and paired helical filament tau aggregates (Auer et al., 1995; Mattsson et al., 2012) . Our results show significantly higher hippocampal Ab40 levels in 10 week old NPC1 À/À mice, comparable to AD patients (Jimenez et al., 2014) . Moreover, these results are in accordance with a study demonstrating a substantial accumulation of Ab in neurons with NPC defect (Jin et al., 2004) .
Since amyloid-b results from processing of APP also the levels of total Amyloid Precursor Protein (APP) in the brain were measured. Multiple studies showed evidence of an increase of APP products such as Ab40, Ab42 and the C-terminal end in the hippocampus of NPC1 À/À mice (Jin et al., 2004; Kodam et al., 2010; Yanez et al., 2016) . Analyzing total cerebellar APP levels showed a progressive increase of APP over age in NPC1 À/À mice. This increase could be related to the increase of Ab40 observed in our study and the fact that redistribution of cholesterol in the NPC1 deficient mouse brain is associated with increased processing of APP (Kodam et al., 2010 ).
Additionally, inflammation was analyzed in the brain showing reduced cerebellar IL-12p70 levels in 6 week old NPC1 À/À mice, confirming the observation in NPC patients showing significantly decreased IL-12p70 levels in the CSF fluid (Cologna et al., 2014) . Furthermore, we show significantly higher hippocampal IL-12p70 levels in 6 week old NPC1 À/À mice that are hence contradicting results in NPC patients. Our analyses of further cytokines did not result in any significant changes in NPC1 À/À mice although Cologna and colleagues already showed increased cytokine levels by qPCR analyses as early as 3 weeks of age. Differences in IL1b levels between these studies might be caused by different analyses methods since Cologna used qPCR measurement of mRNA while we analyzed actual protein levels. Additional markers analyzed by Cologna and coworkers include Ccl3/Mip1a, Ccl8, C3, Cxcl9 and Cxcl10 and therefore differ from cytokines analyzed in the here presented study (Cologna et al., 2014) .
Furthermore, inflammation is a feature that is shared by most neurodegenerative diseases (reviewed by (Chen et al., 2016) ). Interleukin 12 (IL-12) is an inflammatory cytokine that promotes the response of the immune system (Murphy et al., 1994 ; 
Overview of pathologies observed in the cerebellum, hippocampus and cortex of NPC1 À/À mice. Please be aware that 'age in weeks' is defined as the time when pathology is robust. This time is usually later than the age of pathology onset. -: no changes observed; [: increase; Y: decrease; n.s.: not significant; N/ A: not analyzed. Hsieh et al., 2008) . In AD, where Ab levels are increased, an increase of IL-12 can be observed (Hussien et al., 2018) . Here we show significantly higher hippocampal IL12p70 levels in NPC1 À/À mice at 6 weeks of age. Since the accumulation of Ab40 is not significant until 10 weeks, it seems plausible that inflammation precedes and worsens the pathology of Ab40 in NPC disease. As already mentioned, NPC shares some characteristics with AD, including gliosis.
Therefore, we studied GFAP, a glial protein expressed in mature astrocytes, in the NPC1 À/À mouse brain. GFAP is considered a marker for astrocytosis, and known to be induced upon brain damage or during CNS degeneration (for review see (Middeldorp and Hol, 2011) ). In 4 week old NPC1 À/À mice the number of reactive astrocytes was already as high as in 10 week old NPC1 À/À mice thus presenting a similar onset of astrocytosis as already shown by Baudry and co-workers, who showed first signs of astrocytosis as early as 2 weeks of age with a strong increase in the following two weeks of age (Baudry et al., 2003) . Increased reactive astrocytes have also been demonstrated in human post-mortem brain of NPC patients (Chiba et al., 2014; Cologna et al., 2014) , making this pathology relevant for translational NPC1 research. In order to determine whether NPC1 À/À mice show microgliosis, CD45 was examined, an enzyme expressed in microglial cells during CNS inflammation (Ponomarev et al., 2005) . Our results show a progressive increase of CD45 signal in NPC1 À/À mice. Summarizing, these results suggest that NPC1 knock out causes neuroinflammation with a robust phenotype presence already at 4 weeks of age. A summary of results giving the age of robust phenotype presence is listed in Tables 1 and 2 .
Conclusions
In summary, this study confirms an early start of the phenotype in NPC1 À/À mice.
Robust early pathological changes observed in the mouse model are neuroinflammation in the cerebellum as well as loss of brain weight and increase of Ab in the hippocampus. Furthermore, we have also shown that loss of Purkinje cells occurs slightly earlier than motor deficits. Additionally, for the first time a decrease in hippocampal cholesterol levels is demonstrated that is paralleled by severely increased hepatic cholesterol levels. The hepatic and neuronal phenotype is succeeded by general health and motor deficits. Taken together, our results validate already published results, verify the stability of the mice's phenotype, pinpoint the age of robust phenotype presence and thus reinforce the use of these animals to study NPC disease and its possible therapies.
Materials and methods
Animals
All animals were bred and housed under identical conditions in individually ventilated cages on standardized rodent bedding (Rettenmayer ) and normal tap water were available to the animals ad libitum.
Each individual animal was checked regularly for any clinical sign. Male and female animals of equal number were used. Mice were housed in same sex groups of up to four animals. During weaning, less than 1 mm of the tail tip was taken from each animal and used for genotyping. Actual animal numbers are given in the figure legends. All efforts were made to minimize suffering. Heterozygous NPC1 þ/-mice [BALB/cNctr-Npc1<m1N>/J (Jackson Laboratories # 003092)]
were mated and resulting homozygous NPC1 À/À and wildtype NPC1 þ/þ mice used for experiments.
Ethics approval and consent to participate
Animal studies conformed to the Austrian guidelines for the care and use of laboratory animals and were approved by the Styrian government, Austria (ABT13-78Jo-109-2012-1).
Behavioral tests
All behavioral tests were performed during the early phase of the light cycle. Before the start of each behavioral test, animals were habituated to the experimental room for at least 1 hour. Animals were tested in the Rota Rod test and Nest Building Test starting at the age of 5 weeks until 10 weeks of age when animals showed strongest deficits in the motor tests. Beam Walk test was performed at an age of 7 weeks. Animals were allocated to the corresponding experimental group according to their genotype. The body weight was measured using a standard precision scale. The body temperature was measured with a rectal thermometer. The Rota Rod test, Beam walk test and Nest building test were performed as previously described (Rabl et al., 2016 (Rabl et al., , 2017 .
Tissue sampling
All mice were anesthetized by an overdose of the inhalation anesthesia isofluran.
Once animals were deeply anesthetized, the thorax was opened and blood was drawn by heart puncture of the left ventricle and collected in lithium heparin tubes. Mice were afterwards transcardially perfused with physiological (0.9%) saline. Thereafter, liver and brain were taken, brain hemisected and all tissues weight using a precision scale. The right brain hemisphere was fixed by immersion at 4 C in freshly prepared 4% formaldehyde in phosphate buffer (pH 7.4) for 24 hours. After cryo-conservation in a 15% sucrose/phosphate buffered saline (PBS) solution, tissues were shock frozen in dry-ice cooled liquid isopentane and stored at -80 C until used for histological analyses. The left brain hemisphere was further dissected in hippocampus, cortex, cerebellum and remaining brain and all brain parts and the liver immediately shock frozen on dry ice and stored at -80 C until used for biochemical analyses.
Plasma preparation
The blood was centrifuged at 1,000 x g for 10 min at room temperature (RT) and plasma transferred to fresh tubes, frozen on dry ice and stored at -80 C until used for analyses.
Measurement of total cholesterol levels
Liver and brain regions were homogenized with 20% w/v homogenization buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 1% Triton X-100, 2% SDS, and protease and phosphatase inhibitors). For the release of total cholesterol the homogenates were mixed 1:1 with extraction buffer (20 mM TrisHCl, pH 7.4, including 15% Brij 35 and 1% methyl-b-cyclodextrin) (Kirsch et al., 2002) . After 60 min of incubation on a plate shaker, samples were analyzed for total cholesterol levels using the colorimetric assay Fluitest-CHOL (Analyticon, #4241; Lichtenfels, Germany).
Measurement of liver enzymes in plasma
Liver enzymes aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (AP) were analyzed in lithium-heparin plasma samples using the colorimetric assays Fluitest-GOT ASAT, Fluitest-GPT ALAT and Fluitest-AP (Analyticon, #1177; #1187; #1186; Lichtenfels, Germany), respectively.
Measurement of Ab40 and cytokines
Samples were analyzed for Ab40 levels using the MSD Ò 96-well Human (6E10) Ab40 Ultra-Sensitive Kit (#K151FTE-1; Mesoscale Discovery, Rockville, USA) and for cytokine levels using the MSD Ò 96-well V-PLEX Proinflammatory Panel 1 Mouse Kit (#K15048D; Mesoscale Discovery, Rockville, USA). Both immunosorent assays were performed according the manufacturer's protocol.
Histology
Frozen brain hemispheres were cut sagittally on a cryostat (Leica CM3050S). Unless indicated otherwise, a systematic uniform random set of five mounted 10 mm thick brain sections from five medio-lateral levels per animal were used for immunofluorescent labeling.
GFAP þ CD45 þ MAP2 and Calbindin D-28k þ APP incubation of brain sections were conducted as previously described (Rabl et al., 2017) . A list of primary antibodies used for histological labeling is shown in Table 3 .
Whole slide mosaic images of labelled sections were recorded on a fully motorized Zeiss AxioImager Z1 microscope with 10x high aperture lens, equipped with a Zeiss AxioCam MRm camera and ZEN 2.3 software. Mosaic images were merged and converted to full resolution single channel tif files that were used for quantitative image analysis (Fig. 6) . The target area was identified by drawing an area of interest (AOI) on the images. Background correction was used if necessary, and imunofluorescence signals were then quantified by adequate thresholding and morphological filtering (size, shape) to determine the normalized accumulated brightness of all pixels on identified immunopositive objects [signal intensity/mm 2 ]. Once the parameters of the targeted objects had been defined in a test run, the quantitative image analysis ran automatically by a macro so that the results are rater-independent and fully reproducible from the raw images. All measurements were performed using Image Pro Plus (v6.2) software.
Statistics
Data analysis was performed in GraphPad PrismÔ 4.03 (GraphPad Software Inc., USA). Graphs show group means and standard error of the mean (SEM). The significance level was set at p < 0.05. Group means were compared using unpaired t-test or Two-way analysis of variance (ANOVA) with a subsequent post-hoc test. The utilized statistical tests and exact sample numbers are mentioned in the figure legends.
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